Structure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gpcr · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$145
Consensus
$118
+223.1% upside
Low
$90.00
Median: $125 · Last Close: $36.61
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$118.29
223.1% upside
High Target
$145
296.1%
Low Target
$90
145.8%
Current Price
$36.61
as of today
Based on analyst price targets, the GPCR stock price prediction for the next 12 months ranges from $90 to $145. The consensus GPCR price forecast of $118.29 implies 223.1% upside from the current price of $36.61.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $36.05 | ↓ 1.53% |
1-day model range: $35.79–$36.31. Peak: $36.31 (-1.53%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GPCR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-27 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-01-22 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-01-20 | Guggenheim | Maintains | Buy→Buy |
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-12 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-12-12 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-12-11 | Jefferies | Maintains | Buy→Buy |
| 2025-12-09 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Structure Therapeutics Inc. (GPCR) stock. Of the recent 47 rating actions, 0 were upgrades and 0 were downgrades. 14 analysts currently cover GPCR.
Analyst Recommendation Trends
GPCR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$31M
↓ 83.2% YoY
Revenue Next Year
$0M
↓ 99.9% YoY
EPS This Year
$-1.39
EPS Next Year
$-1.94
↑ 39.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast GPCR EPS of $-1.39 for the current fiscal year, based on estimates from 9 analysts. The GPCR revenue forecast is $31M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GPCR stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GPCR price target is $118.29 (+223.1% upside), with an analyst consensus of Buy.
The GPCR short-term stock prediction for tomorrow is $36.05 (-1.53%).
Structure Therapeutics Inc. trades on NASDAQ under the ticker GPCR. The GPCR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
GPCR forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month GPCR price target is $118.29, with a high forecast of $145.00 and a low of $90.00. The median price target is shown in the chart above when available. This implies +223.1% potential upside from the current price of $36.61.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.